FindTrial
Sign In

A Phase III, Randomized, Double-Blinded, Multi-Center, Study to Assess the Efficacy of Docetaxel (TAXOTERE) in Combination With ZD6474 (ZACTIMA) Versus Docetaxel (TAXOTERE) With Placebo in Subjects With Locally Advanced or Metastatic NSCLC

A Phase III, Randomized, Double-Blinded, Multi-Center, Study to Assess the Efficacy of Docetaxel (TAXOTERE) in Combination With ZD6474 (ZACTIMA) Versus Docetaxel (TAXOTERE) With Placebo in Subjects With Locally Advanced or Metastatic NSCLC

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080220351
Enrollment
Unknown
Registered
2007-02-22
Start date
2007-02-22
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-Small Cell Lung Cancer, Lung Cancer

Interventions

investigational material(s) Generic name etc : ZD6474 INN of investigational material : Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material :

Sponsors

AstraZeneca
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Ages Eligible for Study: 18 Years and above Genders Eligible for Study: Both Inclusion Criteria: - Confirmed locally advanced or metastatic NSCLC - Failure of prior 1st line anti-cancer therapy Exclusion Criteria: - Cancer other than NSCLC - Prior treatment with docetaxel - Prior 2nd line anti-cancer therapy

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Safety/Efficacy—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026